跳至主要内容
临床试验/CTRI/2024/02/062769
CTRI/2024/02/062769招募中2 期

A Randomized, Prospective, Comparative, Interventional, Three- Arm, Clinical Trial to Evaluate Efficacy and Safety of Topical Dvija Heal+ in comparison with 1% w/w Framycetin Cream (1% w/w) and Jatyadi Tel in Acute Wounds - Nil

Dvija Naturals Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Subjects who are able to understand instructions and willing to give written informed consent and comply with study protocol.
  • 2. Subjects who agree to have their wound photographed for trial.
  • 3. Subjects with wounds caused by trauma/ Burns (localized burns), Diabetic foot, bed sores, other co- morbid condition, post-operative wound etc. (within 7 days of occurrence)
  • 4. Subjects with superficial and partial thickness wound.
  • 5. Wound size of less than 49 square centimetre.
  • 6. The subject is willing to complete all follow-up evaluations required by the study protocol

排除标准

  • 1. Subjects having a known hypersensitivity to any of the trial medicines or their components.
  • 2. Subjects who have received treatment (another investigational agent) within last thirty days from Screening or Baseline Visit.
  • 3. Subjects are not willing to give informed consent.
  • 4. Pregnant and lactating women.
  • 5. Pediatric subjects.
  • 6. Subjects having clinical evidence of moderate to severe bacterial or fungal infection of the wound as per visual or clinical assessment.
  • 7. Subjects with wound requiring closure by suturing, etc. and or dressing, in the opinion of Investigator or Coinvestigator.
  • 8. Subjects on any other conservative treatment which influences the study results.
  • 9. Subjects with any underlying serious medical illness.
  • 10. Immunocompromised and non- cooperative subjects and or known history of HIV AIDS.
  • 11. Subjects with full thickness wound beyond subcutaneous layer.
  • 12. Subjects with known immunological, hematologic disorders or metastatic malignancy.
  • 13. Subjects having known neurological or psychiatric pathologies.
  • 14. Subjects who have received chemotherapy or radiation therapy within the past 5 years.
  • 15. Subject, who has used any kind of medicines local application and or oral medication for wound within 6 hours prior to Screening or Baseline Visit.
  • 16. Subjects on NSAIDs.
  • 17. Subjects who have received treatment with glucocorticoids for more than 10 consecutive days within 6 months prior to screening or baseline visit or oral corticosteroid with dose more than 10mg per day.
  • 18. Subjects on systemic or topical antibiotics or systemic therapy with cytotoxic drugs.
  • 19. Subjects having severe edema on the treatment target part.

研究者

发起方
Dvija Naturals Pvt Ltd

相似试验